Keating Financial Advisory Services’s Tyra Biosciences TYRA Stock Holding History

Keating Financial Advisory Services’s Portfolio TYRA Stock Details TYRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$32	Buy	+1	New	+$33	﹤0.01%	2549

Other funds holding TYRA

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

APMC

Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Keating Financial Advisory Services's TYRA Position: Q2 2026 in Review

Keating Financial Advisory Services opened a new position in Tyra Biosciences (TYRA) in Q2 2026: 1 share worth $32. The stake represents ﹤0.01% of the portfolio and ranks #2549 among its holdings.

170 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

Keating Financial Advisory Services held 1 share of Tyra Biosciences worth $32 as of Q2 2026.
Tyra Biosciences was a new Keating Financial Advisory Services position in Q2 2026.
Tyra Biosciences made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2549 holding.
170 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.